NASDAQ:RCKT

Rocket Pharmaceuticals Stock Insider Trading

Healthcare > Biotechnology

Buy RCKT

*Your capital is at risk

$3.72

-0.190 (-4.86%)

At Close: Jul 13, 2026

Rocket Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 73.36. In total, the insiders bought 7.75M and sold 517.25K RCKT shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	73.36
● Buy	7.75M shares
● Sell	517.25K shares
58% Buy Activity Strong Negative Correlation
Sell Signal Low Confidence May 26, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory positive Insider Power Score of 73.36. Partially supported by a negative historical correlation. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jul 08, 2026 Buy	Common Stock	Manhede Joseph Principal Accounting Officer	Officer	0 Value: $0
Jun 18, 2026 Buy	Stock Option (Right to Buy) A-Award	Boess Carsten Director	Director	64 860 Value: $217.3K
Jun 18, 2026 Buy	Common Stock A-Award	Fong Peter Director	Director	22 862 Value: $76.6K
Jun 18, 2026 Buy	Common Stock A-Award	Wong Roderick	Director	27 832 Value: $93.2K
Jun 18, 2026 Buy	Stock Option (Right to Buy) A-Award	Wong Roderick	Director	78 960 Value: $264.5K
Jun 18, 2026 Buy	Stock Option (Right to Buy) A-Award	Fong Peter Director	Director	64 860 Value: $217.3K
Jun 18, 2026 Buy	Common Stock A-Award	Dolsten Mikael Director	Director	22 862 Value: $76.6K
Jun 18, 2026 Buy	Stock Option (Right to Buy) A-Award	Dolsten Mikael Director	Director	64 860 Value: $217.3K
Jun 18, 2026 Buy	Stock Option (Right to Buy) A-Award	Malik Fady Ibraham Director	Director	64 860 Value: $217.3K
Jun 18, 2026 Buy	Common Stock A-Award	Malik Fady Ibraham Director	Director	22 862 Value: $76.6K
Jun 18, 2026 Buy	Stock Option (Right to Buy) A-Award	Southwell David P Director	Director	64 860 Value: $217.3K
Jun 18, 2026 Buy	Common Stock A-Award	Southwell David P Director	Director	22 862 Value: $76.6K
Jun 18, 2026 Buy	Common Stock A-Award	Boess Carsten Director	Director	22 862 Value: $76.6K
May 26, 2026 Sell	Stock Option (Right to Buy) D-Return	Militello John See Remarks	Officer	20 000 Value: $454.4K
May 26, 2026 Sell	Stock Option (Right to Buy) D-Return	Militello John See Remarks	Officer	10 000 Value: $108.5K
May 26, 2026 Sell	Stock Option (Right to Buy) D-Return	Militello John See Remarks	Officer	20 000 Value: $291.2K
May 26, 2026 Sell	Stock Option (Right to Buy) D-Return	Militello John See Remarks	Officer	10 000 Value: $206.1K
May 26, 2026 Sell	Stock Option (Right to Buy) D-Return	Militello John See Remarks	Officer	28 910 Value: $379.3K
May 26, 2026 Sell	Stock Option (Right to Buy) D-Return	Militello John See Remarks	Officer	27 003 Value: $514.4K
May 26, 2026 Sell	Stock Option (Right to Buy) D-Return	Militello John See Remarks	Officer	18 000 Value: $1.12M
May 26, 2026 Buy	Stock Option (Right to Buy) A-Award	Militello John See Remarks	Officer	9 091 Value: $27.3K
May 26, 2026 Buy	Stock Option (Right to Buy) A-Award	Militello John See Remarks	Officer	15 002 Value: $45.0K
May 26, 2026 Buy	Stock Option (Right to Buy) A-Award	Militello John See Remarks	Officer	24 899 Value: $74.7K
May 26, 2026 Buy	Stock Option (Right to Buy) A-Award	Militello John See Remarks	Officer	51 509 Value: $154.5K
May 26, 2026 Buy	Stock Option (Right to Buy) A-Award	Militello John See Remarks	Officer	16 061 Value: $48.2K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT ROCKET PHARMACEUTICALS INC

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder ...

Read Full Profile Here